Ranibizumab With and Without Ketorolac Eyedrops for AMDRanibizumab With and Without Ketorolac Eyedrops for AMD
Is ranibizumab more effective with or without the addition of ketorolac eyedrops in the treatment of exudative AMD? This new study takes a look. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
NICE says yes to Lucentis for myopic CNV in fast tracked draft final guidance
In a Final Appraisal Determination (FAD) published October 25, The National Institute for Health and Care Excellence (NICE) has recommended that Lucentis® (ranibizumab) be approved for use within the NHS in England and Wales as an option to treat people with visual impairment due to choroidal neovascularisation associated with pathological myopia (myopic CNV)6. Myopic CNV is the growth of abnormal leaky blood vessels in the back of the eye in high myopia (severe near sightedness)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 28, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Laser Reduces Retreatment in Diabetic Macular EdemaLaser Reduces Retreatment in Diabetic Macular Edema
Laser therapy added to ranibizumab significantly reduced the need for injections in patients with diabetic macular edema. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Cancer drug can treat blindness finds HTA funded research
A cheap cancer drug is just as effective and safe in treating a common cause of loss of vision as an expensive alternative, finds research funded by the NIHR Health Technology Assessment (HTA) Programme. The two year study, which published its results in The Lancet, compared anti-cancer drug Avastin (bevacizumab) with Lucentis (ranibizumab), the drug... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - September 26, 2013 Category: American Health Source Type: news
Monthly Ranibizumab Improves Diabetic RetinopathyMonthly Ranibizumab Improves Diabetic Retinopathy
The severity of diabetic retinopathy is more likely to improve and progression to proliferative disease is less likely to happen when diabetic macular edema is treated with monthly ranibizumab. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Diabetic Macular Edema: Ranibizumab May Offer Good OutcomesDiabetic Macular Edema: Ranibizumab May Offer Good Outcomes
Study's findings must be confirmed in a real-world setting, the investigators warn. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab Effective for Wet Macular DegenerationRanibizumab Effective for Wet Macular Degeneration
Two-year results from the HARBOR trial are in, and they show an individualized treatment approach with ranibizumab is appropriate for treatment-naive patients with age-related macular degeneration. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Bevacizumab, Ranibizumab Improve Vision in Choroidal OsteomaBevacizumab, Ranibizumab Improve Vision in Choroidal Osteoma
Intravitreal injections of antivascular endothelial growth-factor agents are effective in the majority of eyes with choroidal neovascularization. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Lucentis Bests Laser in DME (CME/CE)
(MedPage Today) -- Patients with diabetic macular edema (DME) treated with the costly drug ranibizumab (Lucentis) reported more clinically meaningful improvement in visual functioning than those who received laser treatments alone, according to a new study. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 25, 2013 Category: Consumer Health News Source Type: news
Aflibercept for Exudative AMD Aflibercept for Exudative AMD
How do patients with exudative AMD with persistent fluid on OCT despite receiving regular ranibizumab and/or bevacizumab respond to aflibercept? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
NHS could save £84m using cheaper drug to prevent blindness, trial finds
Researchers say Avastin is just as good as more-expensive Lucentis for treating wet age-related macular degenerationThe NHS could save more than £84m a year if it used a cheap, unlicensed drug to treat people in danger of going blind rather than the expensive one currently licensed and promoted by leading pharmaceutical companies for the purpose, a ground-breaking trial has shown.Researchers led by Prof Usha Chakravarthy from Queen's University Belfast have finally provided an answer to the controversial question of whether the cancer drug Avastin can safely be used to treat people with wet age-related macular degeneratio...
Source: Guardian Unlimited Science - July 18, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian Pharmaceuticals industry News Health Medical research Society UK news Disability Blindness and visual impairment NHS Business Science Source Type: news
Avastin as Good as Lucentis for AMD (CME/CE)
(MedPage Today) -- Bevacizumab (Avastin) appears to have efficacy similar to that of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration, and monthly administration may offer some advantages over as-needed treatment, randomized trial results showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 18, 2013 Category: Consumer Health News Source Type: news
Ranibizumab Injections for Retinopathy of PrematurityRanibizumab Injections for Retinopathy of Prematurity
A new study reports on the 3-year outcomes of infants with ROP treated with intravitreal ranibizumab injections. Are they effective? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Lucentis approved in EU
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 9, 2013 Category: Drugs & Pharmacology Source Type: news
Novartis’ Lucentis gets EU approval to treat pathologic myopia
The European Commission has approved Novartis’ Lucentis (ranibizumab) for the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV). (Source: Drug Development Technology)
Source: Drug Development Technology - July 7, 2013 Category: Pharmaceuticals Source Type: news
